For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||
![]() Philip Morris International IncPM US · Consumer Staples · USD Current price$187.47as of Sep 21, 2026 Summary
Analyst consensusStrong Buy 3Buy 9Hold 415 analysts 3-year price (USD)Factor profileMulti-factor score 72 / 100 Market data
Business descriptionPhilip Morris International is the world's largest publicly traded tobacco company, with a 29.2% share of international cigarette and heated tobacco volumes (excluding China). PM sells 607B cigarettes annually under marquee brands like Marlboro, Parliament, and Virginia Slims, while rapidly pivoting to smoke-free products — ZYN nicotine pouches and IQOS heated tobacco — which now constitute 42% of revenue and 43% of gross profit (2025). Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: $187.47 · Sep 21, 2026· USD
CFRA Ratinghold
TBI Multi Score72
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: PMBusiness description
Philip Morris International is the world's largest publicly traded tobacco company, with a 29.2% share of international cigarette and heated tobacco volumes (excluding China). PM sells 607B cigarettes annually under marquee brands like Marlboro, Parliament, and Virginia Slims, while rapidly pivoting to smoke-free products — ZYN nicotine pouches and IQOS heated tobacco — which now constitute 42% of revenue and 43% of gross profit (2025).
Competitive moat
- Dominant global tobacco market share (29.2% ex-China) with iconic premium brands (Marlboro) providing exceptional pricing power and 67% gross margins among the highest in Consumer Staples.
- First-mover advantage in heated tobacco (IQOS) and nicotine pouches (ZYN), with smoke-free products growing 12.8% in volume and now 42% of revenue.
- High barriers to entry from heavy regulation, excise taxation, and litigation risk protect incumbent positions.
- Stellar earnings track record — only one quarterly miss (Q4 2023) since 2017, reflecting conservative guidance and consistent execution.
- Defensive characteristics: low beta (0.4), 3%+ dividend yield with 18 consecutive years of dividend increases, and ample free cash flow.
Recent developments
- Smoke-free momentum: Smoke-free products reached 42% of revenue in 2025; ZYN nicotine pouches and IQOS driving top-line growth, offsetting cigarette volume declines of 2.2%.
- Q1 2026 beat: Adjusted EPS of $1.96 (+16% Y/Y) ahead of consensus; revenues up 9.1% driven by pricing and smoke-free volume (+9.1%).
- Swedish Match acquisition integration: $14B deal closed in 2022 continues to drive oral product growth; ZYN Ultra launched in U.S. seen as catalyst.
- Currency tailwind: Weakening U.S. dollar providing a $0.25/share EPS benefit in 2026, up from $0.04 in 2025.
Investment risks / red flags
- CFRA is Hold with $175 target: Stock at $192.98 trades above CFRA's $175 target; risk/reward seen as balanced after significant outperformance.
- Regulatory pressure: Italy penalty for misleading "smoke-free" marketing; ongoing global regulatory scrutiny on nicotine products; potential flavor bans and marketing restrictions.
- Secular volume decline: Global cigarette consumption declining ~2% annually; developed markets declining mid-single-digit; any shift in consumer habits away from nicotine would compound headwinds.
- Currency exposure: Despite near-term tailwinds, significant non-U.S. operations create ongoing FX translation risk.
- Elevated debt: Total debt of $51.9B (116% debt/capital) following Swedish Match acquisition; share repurchase program remains suspended.
Market Data
Source: mkts.io · Sep 21, 2026, 20:00 UTC
Key Metrics
P/E (TTM)25.76
P/E (Fwd)20.42
Dividend3.12%
Beta0.40
52W High$207.76
52W Low$142.11
Analyst Consensus
3
9
4
Strong Buy3Buy9Hold415 analysts
Consensus Target$207.40
+10.6% upside
Calendar Events
Next EarningsOct 21, 2026
Ex-DividendOct 2, 2026
Dividend DateOct 26, 2026
Financials
Revenue$42.55B
Rev Growth10.40%
Earnings Growth-7.50%
Gross Margin67.48%
Op Margin40.00%
Profit Margin25.56%
EBITDA$18.02B
ROA14.59%
Rev/Share$27.32
Total Cash$6.00B
Total Debt$49.14B
Free Cash Flow$9.71B
Op Cash Flow$14.26B
Current Ratio0.98
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 2.32 | $11.34B |
| +1q | 1.96 | $11.01B |
| 0y | 8.40 | $43.53B |
| +1y | 9.18 | $46.06B |
Earnings
Quarterly EPS
3Q2025
Est: 2.102.24Beat
4Q2025
Est: 1.701.70Beat
1Q2026
Est: 1.831.96Beat
2Q2026
Est: 2.052.20Beat
Annual
2022
Rev $31.76BEarn $9.05B
2023
Rev $35.17BEarn $7.81B
2024
Rev $37.88BEarn $7.06B
2025
Rev $40.65BEarn $11.35B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Jul 30, 2026 | Citigroup | main | Buy |
| Jul 29, 2026 | Barclays | main | Overweight |
| Jul 23, 2026 | Morgan Stanley | main | Overweight |
| Jul 23, 2026 | Stifel | main | Buy |
| Jul 23, 2026 | Needham | main | Buy |
| Jul 2, 2026 | UBS | main | Neutral |
